Characterization of ibrutinib‐sensitive and ‐resistant mantle lymphoma cells
Jiao Ma(Tongji University), Y. Lynn Wang(Southwest Medical University), Ailin Guo(University of Exeter), Morton Coleman(Cornell University), Pin Lu(University of Chicago), Hongliang Zong(University of Ulster), Shuhua Cheng(Cornell University), Peter Martin(Northwestern University)
Cited by 89
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
|Blood|2015|408
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
|Journal of Clinical Oncology|2009|340